<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pralsetinib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pralsetinib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pralsetinib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="129470" href="/d/html/129470.html" rel="external">see "Pralsetinib: Drug information"</a> and <a class="drug drug_patient" data-topicid="129478" href="/d/html/129478.html" rel="external">see "Pralsetinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58361949"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Pralsetinib Medullary Thyroid Cancer Indication Withdrawn</span>
<span class="collapsible-date">July 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Genentech is voluntarily withdrawing the US indication of Gavreto (pralsetinib) for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years and older who require systemic therapy. Gavreto was granted approval for this indication under the FDA’s Accelerated Approval Program in December 2020. Full approval was contingent upon demonstration of clinical benefit; however, Genentech and Blueprint Medicines decided the study could not be activated to fulfill the postmarketing requirement.</p>
<p style="text-indent:0em;">Further information may be found at https://www.gene.com/media/statements/ps_062923.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54822400"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gavreto</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397563"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Gavreto</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55438665"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, RET Kinase Inhibitor</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Tyrosine Kinase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F55588686"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Select patients for pralsetinib treatment based on the presence of a RET gene fusion (thyroid cancer) or RET gene mutation (medullary thyroid cancer). Withhold pralsetinib for at least 5 days prior to elective surgery; do not administer for at least 2 weeks following major surgery and until adequate wound healing has occurred.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fb79532-fac7-4059-87dc-c2d413450f88">Thyroid cancer, advanced or metastatic, RET fusion-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, advanced or metastatic, RET fusion-positive:</b> Children ≥12 years and Adolescents: Oral: 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c8f5caa-2c24-4856-9b46-c533dce54be0">Thyroid cancer, advanced or metastatic, RET-mutant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer (medullary), advanced or metastatic, RET-mutant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pralsetinib received approval under the FDA's Accelerated Approval Program in December 2020 for the treatment of advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in patients who require systemic therapy (ages ≥12 years and adults); the manufacturer was unable to activate the confirmatory AcceleRET MTC study to fulfill the FDA postmarketing requirement; due to this, the manufacturer has voluntarily withdrawn this indication from the market. This decision is not based on efficacy or safety of pralsetinib and does not affect other approved indications.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Recommended Pralsetinib Dosage Reduction Levels</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Dose reduction level</p></th>
<th align="center">
<p style="text-indent:0em;">Recommended dosage</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Usual (initial dose)</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">300 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">100 mg once daily</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">Permanently discontinue pralsetinib if unable to tolerate 100 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Pralsetinib Dosage Adjustment for Toxicities</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Toxicity</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Pralsetinib dose modification</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemorrhagic events</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pralsetinib until recovery to baseline or grade 0 or 1.</p>
<p style="text-indent:0em;">Permanently discontinue pralsetinib for severe or life-threatening hemorrhagic events.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Hypertension</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Initiate or optimize antihypertensive therapy. Withhold pralsetinib for grade 3 hypertension that persists despite management with optimal antihypertensive therapy. Resume pralsetinib at a reduced dose when hypertension is controlled.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue pralsetinib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Pulmonary toxicity (interstitial lung disease [ILD])/pneumonitis)</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pralsetinib until resolution, then resume pralsetinib at a reduced dose. Permanently discontinue pralsetinib for recurrent ILD/pneumonitis.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue pralsetinib for confirmed ILD/pneumonitis.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold pralsetinib until improvement to ≤ grade 2, then resume pralsetinib at a reduced dose.</p>
<p style="text-indent:0em;">Permanently discontinue pralsetinib for recurrent grade 4 adverse reactions.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F55590177"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, based on adult data, CrCl 30 to 89 mL/minute had no effect on pralsetinib exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F55590178"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild (total bilirubin ≤ ULN with AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN with any AST) impairment: No dosage adjustment is required.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment:</i> Grade 3 or 4: Withhold pralsetinib and monitor AST and ALT once weekly until resolves to grade 1 or baseline. Resume pralsetinib at a reduced dose. If ≥ grade 3 hepatotoxicity recurs, discontinue pralsetinib. See recommended pralsetinib dosage reduction levels in "Dosing Adjustment for Toxicity."</p></div>
<div class="block doa drugH1Div" id="F54830450"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="129470" href="/d/html/129470.html" rel="external">see "Pralsetinib: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Select patients for pralsetinib treatment based on the presence of a RET gene fusion. Optimize BP prior to initiating treatment; do not initiate pralsetinib in patients with uncontrolled hypertension. Withhold pralsetinib for at least 5 days prior to elective surgery; do not administer for at least 2 weeks following major surgery and until adequate wound healing has occurred.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85a4d27e-252c-4f96-9d17-0942c36dd895">Non–small cell lung cancer, metastatic, RET fusion-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, RET fusion-positive: Oral:</b> 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fb79532-fac7-4059-87dc-c2d413450f88">Thyroid cancer, advanced or metastatic, RET fusion-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, advanced or metastatic, RET fusion-positive:</b>
<b>Oral:</b> 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bff28250-e5e5-4fc4-9a9a-8c3961688310">Thyroid cancer, medullary, advanced or metastatic, RET-mutant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid cancer, medullary, advanced or metastatic, RET-mutant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pralsetinib received approval under the FDA's Accelerated Approval Program in December 2020 for the treatment of advanced or metastatic REarranged during Transfection (RET)-mutant medullary thyroid cancer (MTC) in patients who require systemic therapy; the manufacturer was unable to activate the confirmatory MTC study to fulfill the FDA postmarketing requirement and has voluntarily withdrawn this indication from the market. This decision is not based on efficacy or safety of pralsetinib and does not affect other approved indications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, administer as soon as possible on the same day; resume the regular daily pralsetinib dose schedule the following day. If vomiting occurs after pralsetinib administration, do not take an additional dose and continue to the next scheduled time for the next dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54830452"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, CrCl 30 to 89 mL/minute had no effect on pralsetinib exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to 30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54830453"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild (total bilirubin ≤ ULN with AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN with any AST) impairment:</i> No dosage adjustment is required.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (total bilirubin &gt;3 times ULN and any AST) impairment:</i> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment: </b>Grade 3 or 4: Withhold pralsetinib and monitor AST and ALT once weekly until resolves to grade 1 or baseline. Resume pralsetinib at a reduced dose. If ≥ grade 3 hepatotoxicity recurs, discontinue pralsetinib. See recommended pralsetinib dosage reduction levels in "Dosing - Adjustment for Toxicity."</p></div>
<div class="block arsc drugH1Div" id="F54997485"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity</b>, including grade 3 or grade 4 hepatotoxicity, has been observed with pralsetinib. <b>Increased serum alanine aminotransferase</b> (ALT) and <b>increased serum aspartate aminotransferase</b> (AST) commonly occurs. Some patients required treatment interruption, dose reduction, and/or permanent discontinuation, depending on severity of hepatoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median time to first onset of elevated AST was 15 days (range: 5 days to 2.5 years); the median time to first onset of elevated ALT was 22 days (range: 7 days to 3.7 years).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension </b>commonly occurs with use, with almost half of these patients developing grade 3 hypertension. Although antihypertensive medication was the most common method used to manage treatment-emergent hypertension, some patients required treatment interruption, dose reduction, and/or permanent discontinuation, depending on severity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; exact mechanism is not established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting uncontrolled hypertension</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, life-threatening, and potentially fatal interstitial lung disease (ILD)/<b>pneumonitis</b> may occur with pralsetinib. Pneumonitis was commonly reported, including some grade 3 and 4 events; fatal pneumonitis occurred rarely. Withhold therapy and promptly evaluate patients with symptoms indicative of ILD. Therapy interruption, dose reduction, and/or permanent pralsetinib discontinuation may be necessary based on the severity of confirmed ILD.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tumor lysis syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>tumor lysis syndrome</b> have been reported in patients treated with pralsetinib for medullary thyroid cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of rapidly growing tumors</p>
<p style="text-indent:-2em;margin-left:6em;">• High tumor burden</p>
<p style="text-indent:-2em;margin-left:6em;">• Renal dysfunction</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Wound healing impairment</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib may have the potential to adversely affect wound healing. Due to this concern, recommendations regarding withholding therapy prior to elective surgery and/or after major surgery exist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exact mechanism is unknown; vascular endothelial growth factor receptor inhibitors are associated with impaired wound healing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Major surgery</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54820549"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (29% to 44%), hypertension (35% to 40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (17% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (41% to 52%), decreased serum calcium (corrected: 50% to 70%), decreased serum magnesium (25% to 27%), decreased serum phosphate (28% to 50%), decreased serum potassium (27%), decreased serum sodium (28% to 42%), hypermagnesemia (14%), increased serum phosphate (40%), increased serum potassium (26% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14% to 17%), constipation (41% to 45%), decreased appetite (15% to 18%), diarrhea (30% to 34%; grades 3/4: 3% to 5%, including colitis), dysgeusia (17%), nausea (17% to 19%; grade 3: &lt;1%), stomatitis (6% to 17%; grade 3: &lt;1%), vomiting (14%), xerostomia (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (63% to 78%; grades 3/4: 13% to 18%), decreased neutrophils (59% to 70%; grades 3/4: 16% to 21%), decreased platelet count (31% to 33%; grades 3/4: 3% to 5%), leukopenia (79%; grades 3/4: 11%), lymphocytopenia (67% to 73%; grades 3/4: 27% to 32%), tumor lysis syndrome (&lt;15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (37% to 58%), increased serum alkaline phosphatase (22% to 43%), increased serum aspartate aminotransferase (49% to 80%), increased serum bilirubin (20% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (19%), fatigue (38% to 42%, including asthenia), headache (15% to 24%), peripheral neuropathy (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (≤19%), musculoskeletal pain (42% to 44%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (41% to 45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (27% to 36%), dyspnea (21% to 22%), pneumonia (24%), pneumonitis (12% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (22% to 29%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (grades ≥3: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (severe: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (≥2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Cardiovascular: Heart failure (Papaila 2021), pleural effusion (Papaila 2021)</p></div>
<div class="block coi drugH1Div" id="F54816079"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to pralsetinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54830437"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Cases of tumor lysis syndrome (TLS) have been reported with pralsetinib in patients with medullary thyroid cancer. The risk for TLS is increased in patients with rapidly growing tumors, a high tumor burden, kidney dysfunction, or dehydration. Assess risk for TLS; consider appropriate prophylaxis (including hydration) and manage as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• RET gene status: Select patients for pralsetinib treatment based on the presence of a RET gene fusion. Information on approved tests is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=131031" target="_blank">http://www.fda.gov/CompanionDiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F54822401"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gavreto: 100 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block geq drugH1Div" id="F54822399"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54868177"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Gavreto Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $222.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397564"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gavreto: 100 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block accres drugH1Div" id="F54830428"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Pralsetinib is available through a specialty pharmacy network and specialty distributors; information may be found at https://gavreto.com/.</p></div>
<div class="block admp drugH1Div" id="F55590179"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach; no food or meal at least 2 hours before dose and at least 1 hour after. If vomiting occurs after pralsetinib administration, do not take an additional dose; continue to the next scheduled time for the next dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed, administer as soon as possible on the same day; resume the regular daily pralsetinib dose schedule the following day.</p></div>
<div class="block adm drugH1Div" id="F54830455"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer on an empty stomach at least 1 hour before and at least 2 hours after a meal or food.</p></div>
<div class="block hazard drugH1Div" id="F54830440"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Pralsetinib may cause reproductive toxicity and teratogenicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F54830441"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F55588681"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pralsetinib received approval under the FDA's Accelerated Approval Program in December 2020 for the treatment of advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in patients who require systemic therapy (ages ≥12 years and adults); the manufacturer was unable to activate the confirmatory AcceleRET MTC study to fulfill the FDA postmarketing requirement; due to this, the manufacturer has voluntarily withdrawn this indication from the market. This decision is not based on efficacy or safety of pralsetinib and does not affect other approved indications.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of advanced or metastatic RET fusion-positive thyroid cancer in patients who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) (FDA approved in ages ≥12 years and adults); treatment of advanced or metastatic RET-mutant medullary thyroid cancer in patients who require systemic therapy (FDA approved in ages ≥12 years and adults); treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an approved test (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F54830427"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pralsetinib may be confused with pazopanib, pemigatinib, pexidartinib, ponatinib, pralatrexate, ripretinib, selpercatinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54846699"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54846696"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Pralsetinib. Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Pralsetinib. Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Pralsetinib. Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pralsetinib. Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Moderate) and P-glycoprotein: May increase the serum concentration of Pralsetinib. Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Pralsetinib. Management: Avoid concomitant use if possible. If combined, reduce the pralsetinib dose. If taking 400 mg or 300 mg once daily, reduce to 200 mg once daily. If taking 200 mg once daily, reduce to 100 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Pralsetinib. Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: Consider avoiding use of sotorasib and narrow therapeutic index/sensitive P-gp substrates. If combined use is unavoidable, monitor for increased toxicities of the substrate and consider a decrease in the substrate dosage.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F54830439"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Following administration of a single 200 mg pralsetinib dose with a high-fat meal (~800 to 1<b>,</b>000 calories with 50% to 60% of calories from fat), the mean C<sub>max</sub> and AUC<sub>0-inf</sub> were increased by 104% and 122%, respectively, compared to the fasting state; the median T<sub>max</sub> was delayed from 4 to 8.5 hours. Management: Administer pralsetinib on an empty stomach at least 1 hour before and at least 2 hours after a meal or food.</p></div>
<div class="block rep_considerations drugH1Div" id="F54830435"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective nonhormonal contraception during therapy and for 2 weeks after the last pralsetinib dose. Patients with partners who could become pregnant should also use effective contraception during therapy and for 1 week after the last dose of pralsetinib.</p></div>
<div class="block pri drugH1Div" id="F54830434"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to pralsetinib may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F55590180"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Evaluate RET gene fusion status (thyroid cancer) or RET gene mutation (medullary thyroid cancer). Monitor ALT and AST baseline, every 2 weeks during the first 3 months of therapy, then monthly thereafter, and as clinically indicated. Hepatitis B virus screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning systemic anticancer therapy (ASCO [Hwang 2020]). Evaluate pregnancy status prior to use in females of reproductive potential. Monitor BP at baseline, after 1 week, at least monthly thereafter, and as clinically indicated. Monitor for signs/symptoms of interstitial lung disease/pneumonitis, hemorrhage, tumor lysis syndrome (in patients with medullary thyroid cancer), and impaired wound healing. Monitor adherence. Monitor growth plates in adolescent patients with open growth plates.</p></div>
<div class="block pha drugH1Div" id="F54830442"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pralsetinib inhibits wild-type RET (REarranged during Transfection), oncogenic RET fusions (CCDC6-RET) and RET mutations (RET V804L, RET V804M, and RET M918T); in enzyme assays, pralsetinib also inhibited DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1. Certain activating point mutations in RET or chromosomal rearrangements involving in-frame fusions of RET can result in constitutively activated chimeric RET fusion proteins, which may act as oncogenic drivers, promoting tumor cell line proliferation. Pralsetinib has demonstrated antitumor activity in cells harboring oncogenic RET fusions or mutations including CCDC6-RET, KIF5B-RET, RET M918T, RET C634W, RET V804L, and RET V804M.</p></div>
<div class="block phk drugH1Div" id="F54830460"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic data in pediatric patients ≥12 years was shown to be similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Adults: V<sub>d</sub>/F: 303 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Predominantly via CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: Single dose: ~16 hours; multiple doses: ~20 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Adults: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Adults: Feces: ~73% (66% as unchanged drug); urine: ~6% (~5% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Adults: 10.9 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216282"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gavreto</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gavreto.1">
<a name="Gavreto.1"></a>Gavreto (pralsetinib) [prescribing information]. South San Francisco, CA: Genentech Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gavreto.1">
<a name="Gavreto.1"></a>Gavreto (pralsetinib) [prescribing information]. South San Francisco, CA: Genentech Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Gavreto (pralsetinib) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralsetinib-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralsetinib-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34258110">
<a name="34258110"></a>Papaila A, Jacobson AT. Into the unknown: a case of new-onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, pralsetinib. <i>Cureus</i>. 2021;13(6):e15441. doi:10.7759/cureus.15441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralsetinib-pediatric-drug-information/abstract-text/34258110/pubmed" id="34258110" target="_blank">34258110</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed September 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pralsetinib-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 131031 Version 51.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
